211 related articles for article (PubMed ID: 31203509)
1. Management of bone health in patients with cancer: a survey of specialist nurses.
Drudge-Coates L; van Muilekom E; de la Torre-Montero JC; Leonard K; van Oostwaard M; Niepel D; Jensen BT
Support Care Cancer; 2020 Mar; 28(3):1151-1162. PubMed ID: 31203509
[TBL] [Abstract][Full Text] [Related]
2. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
3. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional study on Chinese oncology nurses' knowledge of bone health among cancer patients.
Shan J; Lv S; Chen L; Li T; Li J; Wang S; Zhang C
Support Care Cancer; 2023 Aug; 31(8):501. PubMed ID: 37526757
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic approaches for protecting bone health in patients with breast cancer.
Lüftner D; Niepel D; Steger GG
Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
7. [Cancer Treatment-Induced Bone Loss(CTIBL)].
Fukumoto S; Matsumoto T
Gan To Kagaku Ryoho; 2018 Dec; 45(12):1685-1689. PubMed ID: 30587719
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for cancer-related bone loss.
Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
[TBL] [Abstract][Full Text] [Related]
9. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
10. Moving into the future: treatment of bone metastases and beyond.
Hortobagyi GN
Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
[TBL] [Abstract][Full Text] [Related]
12. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Takahashi S
Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
14. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
17. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
18. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Brufsky AM
Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
[TBL] [Abstract][Full Text] [Related]
19. Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.
Dionísio MR; Mansinho A; Abreu C; Cavaco-Silva J; Casimiro S; Costa L
Br J Clin Pharmacol; 2019 Jun; 85(6):1114-1124. PubMed ID: 30601585
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]